פינלנד - פינית - Fimea (Suomen lääkevirasto)

janssen-cilag oy - epoetinum alfa - injektioneste, liuos, esitäytetty ruisku - 4000 iu/ml - epoetiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

janssen-cilag oy - epoetinum alfa - injektioneste, liuos, esitäytetty ruisku - 10000 iu/ml - epoetiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

janssen-cilag oy - epoetinum alfa - injektioneste, liuos, esitäytetty ruisku - 40 000 iu/ml - epoetiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

ferring lÄÄkkeet oy - menotropine - injektioneste, liuos, esitäytetty kynä - 1200 iu - menotropiini

פינלנד - פינית - Fimea (Suomen lääkevirasto)

ferring lÄÄkkeet oy - menotropine - injektioneste, liuos, esitäytetty kynä - 600 iu - menotropiini

האיחוד האירופי - פינית - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

האיחוד האירופי - פינית - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

האיחוד האירופי - פינית - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - rokotteet - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. käyttö tämä rokote tulee virallisten suositusten mukaisesti.

האיחוד האירופי - פינית - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilia a - hemostaatit - verenvuodon hoito ja ehkäisy potilailla, joilla on hemofilia a (synnynnäinen tekijä viii -häiriö). tämä valmiste ei sisällä von willebrand-tekijää ja on näin ollen ei ole tarkoitettu von willebrandin taudin hoitoon.

פינלנד - פינית - Fimea (Suomen lääkevirasto)

prothya biosolutions netherlands b.v. - human normal immunoglobulin - infuusioneste, liuos - 50 mg/ml - ihmisen normaali immunoglobuliini intravaskulaariseen käyttöön